• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results

Posted on: Thursday, 5 February 2009, 07:30 CST

ATLANTA, Feb. 5 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that 2008 fourth quarter and year end financial results will be released on Thursday, February 19, 2009. The Company will hold a teleconference call and live webcast at 10:00 a.m. Eastern Time, February 19, 2009, to discuss the results, followed by a question and answer session hosted by Steven G. Anderson, president and CEO of CryoLife, Inc.

To listen to the live teleconference, please dial 201-689-8261 a few minutes prior to 10:00 a.m. A replay of the teleconference will be available February 19 through February 26 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The account number for the replay is 244 and the conference number is 312509.

The live webcast and replay can be accessed by going to the Investor Relations section of the CryoLife web site at www.cryolife.com and selecting the heading Webcasts & Presentations.

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the U.S. and Canada. The Company recently received FDA clearance for the CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. CryoLife distributes Hemostase MPH, a hemostatic agent, in much of the U.S. for use in cardiac and vascular surgery and in the United Kingdom, Germany, France and Canada for cardiac, vascular, and general surgery, subject to certain exclusions. The Company also distributes the CryoLife-O'Brien(R) Stentless Porcine Aortic Bioprosthesis, which is CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site:

http://www.cryolife.com.

D. Ashley Lee Katie Brazel Executive Vice President, Fleishman Hillard Chief Financial Officer and Phone: 404-739-0150 Chief Operating Officer Phone: 770-419-3355

SOURCE CryoLife, Inc.

Source: PR Newswire

More News in this Category